QuidelOrtho Corporation QDEL Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

Idexx LaboratoriesIDXX

$32.31M+20.5%

Charles River LaboratoriesCRL

——

Butterfly NetworkBFLY

——

Thermo Fisher ScientificTMO

——

Other financials

Income statement

See full

Revenue$619.8M-10.5%

Gross profit$263.8M-23.2%

Operating income-$31.8M-198%

Net income-$91.8M-623%

EPS (diluted)-$1.35-611%

Balance sheet

See full

Cash & equivalents$140.4M+10.4%

Total debt$3.1B+0.3%

Total equity$1.9B-38.2%

Total assets$5.6B-12.9%

Cash flow

See full

Operating cash flow-$33.0M-150%

CapEx$34.0M-39.5%

Free cash flow-$67.0M-813%

Valuation

See full

Market cap$921.94M-51.4%

Enterprise value$3.88B-20.1%

P/S0.4×-0.3×

Profitability

See full

Gross margin45%-2.0pp

Operating margin-37%-46.2pp

Net margin-45.6%-75.7pp

FCF margin13.8%—

Returns & leverage

See full

Return on equity-49.9%-70.8pp

Debt / equity1.7×+0.6×

Current ratio1.4×+0.2×

Where this comes from

Reported directly by QuidelOrtho Corporation in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: QuidelOrtho Corporation’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about QuidelOrtho Corporation's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is QuidelOrtho Corporation's deferred revenue, net of current portion?: QuidelOrtho Corporation (QDEL) reported deferred revenue, net of current portion of $16.7M in Q1 2026.